The U.S. Food and Drug Administration (FDA) approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).
The U.S. Food and Drug Administration approved once-daily Veramyst? (fluticasone furoate) Nasal Spray to treat seasonal and year-round allergy symptoms in adults and children two years of age and older. Veramyst will be available by prescription nationwide by late May 2007.
A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.
Scientists and a former supermodel are joining forces to promote healthier practices within the fashion industry as part of the Academy for Eating Disorders (AED) international conference in Baltimore, Maryland, May 2-5, 2007.
Mailing a simple information pamphlet to interested drinkers in the general population reduced binge drinking by 10 per cent, and is a promising public health approach to reduce the health and social problems associated with heavy drinking, shows a new study led by the University of Alberta.
On the occasion of the 2nd International Congress on Prediabetes and the Metabolic Syndrome held in Barcelona, Spain, April 25-28, 2007, the initiation of the Acarbose Cardiovascular Evaluation (ACE) was announced.
Bristol-Myers Squibb Company (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has approved an update to the ORENCIA? (abatacept) product labeling regarding the progression of structural joint damage — an important measure in the treatment of rheumatoid arthritis (RA).
Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for SINGULAIR? (montelukast sodium) to prevent exercise-induced bronchoconstriction (EIB; also known as exercise-induced asthma) in patients aged 15 years and older.
Roche announces several new research initiatives to further study the use of Tamiflu against the evolving H5N1 avian influenza virus and outlined the future production strategy for Tamiflu.
Solvay announced that its dossier for intravenous tedisamil (intended brand name: PULZIUM? IV), a new chemical entity coming from Solvay Pharmaceuticals R&D laboratories, has been filed for approval by the US Food and Drug Administration (FDA) as well as by the authorities of European U nion countries.